Europe Plasma Protein Therapeutics Market Growth, Size, Trends, Share, Scope and Future Outlook
Europe Plasma Protein Therapeutics Market Size- By End User, By Product Type, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Apr-2024 | Report ID: HLCA2441 | Pages: 1 - 155 | Formats*: |
| Category : Healthcare | |||
Europe Plasma Protein Therapeutics Market Introduction and Overview
According to SPER Market Research, the Europe Plasma Protein Therapeutics Market is estimated to reach USD 16320.44 million by 2033 with a CAGR of 6.12%.
The report includes an in-depth analysis of the Europe Plasma Protein Therapeutics Market, including market size and trends, product mix, distribution channels, and supplier analysis. A class of medications known as plasma protein therapies is derived from proteins present in human blood plasma. These proteins provide a variety of biological tasks for the body, such as controlling immunological response, blood coagulation, and fluid balance. A variety of illnesses, such as bleeding disorders, immunological deficits, and genetic abnormalities, are treated with plasma protein therapies. They must be closely monitored to guarantee correct dosage and reduce any possible adverse effects. They are frequently given by injection or infusion.
Grifols opened a brand-new, cutting-edge production facility in Ireland in October 2022 to fulfill the rising demand for plasma therapies worldwide. The most abundant plasma protein, albumin, is in greater demand than ever, therefore Grifols' Dublin manufacturing facility triples the yearly filling capacity of its novel, flexible container, ALBUTEIN FlexBag. The Rika Plasma Donation System (Rika), created by Terumo Blood and Cell Technologies (Terumo BCT), a medical technology business, was approved by the Food and Drug Administration (FDA) in March 2022.
Market Opportunities and Challenges
Opportunities: The rising incidence of autoimmune diseases, immune deficiency illnesses, neurological and bleeding disorders, and the expansion of plasma protein research and development are the main drivers of the market's growth. Furthermore, normal blood clotting is hindered by the rare inherited bleeding condition hemophilia. Uncontrolled bleeding, often in several body parts, is the primary sign of this condition. The degree of hemophilia dictates how much bleeding occurs. Future growth in the market is anticipated since hemophilia is becoming more and more common among patients. Additionally, throughout the course of the forecast period, rising corporate activities and research and development (R&D) of novel treatments are anticipated to support segment expansion.
Challenges: The European market for plasma protein therapeutics is faced with some significant challenges. First of all, the licensing and commercialization of products produced from plasma are frequently delayed by regulatory obstacles and strict quality standards, which restricts market access for both existing and growing businesses. Furthermore, variations in the demand and supply of plasma, which are impacted by variables including donor accessibility and prevailing economic conditions, can cause delays in manufacturing schedules and shortages in the material. Market share and pricing strategies are also threatened by the growing competition from biosimilar drugs and other treatment techniques. Moreover, patient access to plasma protein therapies may be restricted by reimbursement concerns and healthcare budgetary restraints in certain European nations, which may have an effect on market expansion.
Market Competitive Landscape
The Plasma Protein Therapeutics Market in Europe is moderately consolidated. Some of the market key players are Abeona Therapeutics Inc., ADMA Biologics Inc., Baxter International Inc., Bayer AG, CSL Limited (CSL Behring), Grifols, S.A., Kedrion S.p.A, Octapharma AG, Taibang Biological Group Co., Ltd, Takeda Pharmaceutical Company Limited, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By End User, By Product Type, By Application |
| Regions covered | UK, France, Germany, Italy, Spain, Rest of Europe |
| Companies Covered | Abeona Therapeutics Inc., ADMA Biologics Inc., Baxter International Inc., Bayer AG, CSL Limited (CSL Behring), Grifols, S.A., Kedrion S.p.A, Octapharma AG, Taibang Biological Group Co., Ltd, Takeda Pharmaceutical Company Limited, Others. |
COVID-19 Impact on Europe Plasma Protein Therapeutics Market
The early stages of the COVID-19 pandemic had a major effect on the plasma protein therapies business due to factors like decreased plasma donations, lab and testing center closures, and import and export restrictions on medications. But once the limitations were removed, the industry has been thriving again. Due to more product launches for plasma protein therapies and related research investigations, the market is anticipated to expand.
Key Target Audience:
- Healthcare Providers
- Pharmaceutical Companies
- Research Institutions
- Regulatory Agencies
- Patients
- Distributors
- Investors
Our in-depth analysis of the Europe Plasma Protein Therapeutics Market includes the following segments:
| By End User: |
|
| By Product Type: |
|
| By Region: |
|
Key Topics Covered in the Report:
- Europe Plasma Protein Therapeutics Market Size (FY’2024-FY’2033)
- Overview of Europe Plasma Protein Therapeutics Market
- Segmentation of Europe Plasma Protein Therapeutics Market By End User (Hospitals, Others)
- Segmentation of Europe Plasma Protein Therapeutics Market By Product Type (Immunoglobulin, Albumin, Plasma derived factor VIII, Other)
- Segmentation of Europe Plasma Protein Therapeutics Market By Application (Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, Others)
- Expansion Analysis of Europe Plasma Protein Therapeutics Market
- Problems and Obstacles in Europe Plasma Protein Therapeutics Market
- Competitive Landscape in the Europe Plasma Protein Therapeutics Market
- Impact of COVID-19 and Demonetization on Europe Plasma Protein Therapeutics Market
- Details on Current Investment in Europe Plasma Protein Therapeutics Market
- Competitive Analysis of Europe Plasma Protein Therapeutics Market
- Prominent Players in the Europe Plasma Protein Therapeutics Market
- SWOT Analysis of Europe Plasma Protein Therapeutics Market
- Europe Plasma Protein Therapeutics Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Europe Plasma Protein Therapeutics Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Plasma Protein Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Plasma Protein Therapeutics Market
7. Europe Plasma Protein Therapeutics Market, By End User (USD Million) 2020-2033
7.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By End User, 2020-20267.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By End User, 2027-20337.3. Hospitals7.4. Others
8. Europe Plasma Protein Therapeutics Market, By Product Type (USD Million) 2020-2033
8.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Product Type, 2020-20268.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Product Type, 2027-20338.3. Immunoglobulin8.4. Albumin8.5. Plasma derived factor VIII8.6. Other
9. Europe Plasma Protein Therapeutics Market, By Application (USD Million) 2020-2033
9.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Application, 2020-20269.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Application, 2027-20339.3. Idiopathic Thrombocytopenic Purpura9.4. Primary Immunodeficiency Disorder9.5. Others
10. Europe Plasma Protein Therapeutics Market Forecast, 2020-2033 (USD Million)
10.1. Europe Plasma Protein Therapeutics Market Size and Market Share
11. Europe Plasma Protein Therapeutics Market, By Region, 2020-2033 (USD Million)
11.1. Europe Plasma Protein Therapeutics Market Size and Market Share By Region (2020-2026)11.2. Europe Plasma Protein Therapeutics Market Size and Market Share By Region (2027-2033)11.3. France11.4. Germany11.5. Italy11.6. United Kingdom11.7. Rest of Europe
12. Company Profile
12.1. Abeona Therapeutics Inc.12.1.1. Company details12.1.2. Financial outlook12.1.3. Product summary12.1.4. Recent developments12.2. ADMA Biologics Inc.12.2.1. Company details12.2.2. Financial outlook12.2.3. Product summary12.2.4. Recent developments12.3. Baxter International Inc.12.3.1. Company details12.3.2. Financial outlook12.3.3. Product summary12.3.4. Recent developments12.4. Bayer AG12.4.1. Company details12.4.2. Financial outlook12.4.3. Product summary12.4.4. Recent developments12.5. CSL Limited (CSL Behring)12.5.1. Company details12.5.2. Financial outlook12.5.3. Product summary12.5.4. Recent developments12.6. Grifols, S.A.12.6.1. Company details12.6.2. Financial outlook12.6.3. Product summary12.6.4. Recent developments12.7. Kedrion S.p.A12.7.1. Company details12.7.2. Financial outlook12.7.3. Product summary12.7.4. Recent developments12.8. Octapharma AG12.8.1. Company details12.8.2. Financial outlook12.8.3. Product summary12.8.4. Recent developments12.9. Taibang Biological Group Co., Ltd12.9.1. Company details12.9.2. Financial outlook12.9.3. Product summary12.9.4. Recent developments12.10. Takeda Pharmaceutical Company Limited12.10.1. Company details12.10.2. Financial outlook12.10.3. Product summary12.10.4. Recent developments12.11. Others
13. List of Abbreviations
14. Reference Links
15. Conclusion
16. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Europe Plasma Protein Therapeutics Market is projected to reach USD 16320.44 million by 2033, growing at a CAGR of 6.12% during the forecast period.
Europe Plasma Protein Therapeutics Market size from 2022. The Market is expected to reach USD 16320.44 million by 2033, at a CAGR of 6.12% during the forecast period.
Europe Plasma Protein Therapeutics Market CAGR of 6.12% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Europe Plasma Protein Therapeutics Market size is16320.44 million from 2024 to 2033.
Europe Plasma Protein Therapeutics Market Segment is covered By End User, By Product Type, By Application.
The Europe anticipated to have the highest market share in the Europe Plasma Protein Therapeutics Market.
The key players in the market include Companies Covered Abeona Therapeutics Inc., ADMA Biologics Inc., Baxter International Inc., Bayer AG, CSL Limited (CSL Behring), Grifols, S.A., Kedrion S.p.A, Octapharma AG, Taibang Biological Group Co., Ltd, Takeda Pharmaceutical Company Limited, Others.
Moreover, patient access to plasma protein therapies may be restricted by reimbursement concerns and healthcare budgetary restraints in certain European nations, which may have an effect on market expansion.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
